Morning Trend | MEDSCI funds are on the sidelines, will it be a volume-driven surge or a defensive approach?

MEDSCI (2415.HK) continued to perform poorly yesterday, with the pharmaceutical sector lacking positive stimuli and a bearish sentiment prevailing. Although there was an initial attempt to rise at the beginning of the trading session, it quickly fell back. The overall phenomenon is characterized by converging trading volume and a wait-and-see attitude from major players, with industry news being bleak and the company lacking announcements to provide support, resulting in a severe lack of short-term driving force. The MACD remains in a death cross, indicating a significant weak pattern, and both RSI and the volume-price relationship are not ideal. HKD 1.47 has become a key support zone, with a clear willingness from market leaders to defend it. If it comes under pressure but receives capital replenishment, there may be a partial rebound; conversely, a weak rebound is likely to become a false signal for bullishness. During the trading session, it is essential to closely monitor policy news and capital movements. If there are no significant marginal changes, the risk of high short-term volatility will continue to exist, and investors should focus on risk management